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INTRODUCTION 
 Acute undifferentiated febrile illness (AUFI) defined as acute onset of 
fever less than 14 days of duration without any evidence of organ or 
systemic specific aetiology(5).  No cause found after full history and physical 
examination (1).  AUFI also known as short febrile illness or acute fever or 
acute febrile illness. Acute undifferentiated febrile illness different from 
“pyrexia of unknown origin” in which fever persist for longer duration most 
probably more than three weeks(2). Climate variation over population and 
urbanization may all contribute to the emergence and reemergence of 
infections in tropical regions. (singh et al, 2012)(10). 
     
 The aetiologies of acute febrile illness can vary region wise in India 
suggesting that diagnosis, treatment, and control programs need to be based 
on a methodical evaluation of area specific etiologies(11). Knowledge of 
local prevalence of infections is essential for areas. The commonest causes 
include malaria, chikungunya, dengue, scrub typhus, leptospirosis, typhoid 
fever.  
    
 The great diversity of AUFI etiologies are a challenge of diagnosis, 
treatment and public health responses to endemic and epidemic disease. 
Given confusion in distinguishing between AUFI, inappropriate use of 
antibiotics is rampant, frequently by improperly interpreted tests(9). 
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 The lacking of proper diagnostic tools are usually unable to determine 
specific aetiologies often diagnosing patients presumptively based on 
clinical features and regarding causative organisms. Clinical features can 
help in syndrome diagnosis of AUFI (6). 
    
Early diagnosis and management of acute undifferentiated febrile 
illness are necessary as delay in diagnosis and appropriate antibiotic 
administration can lead to increased mortality(10). Infectious diseases are 
leading causes of mortality and death in topical countries. The World Health 
Organisation (WHO) reports that each of the main infectious aetiologies 
cause between 1.05 and 0.24 million deaths respectively per year in low 
income. Countries(7). In resource limited settings fever may be treated 
empirically or self treated due to lack of access to diagnostic tests(12). 
     
Number of bacteria, viruses, protozoa and rickettsiae can cause AUFI. 
    
 It is important to maintain a proper epidemiological data of AUFI so 
that evidence based diagnostic criteria and treatment guidelines can be 
developed.  . Health care providers lacking proper diagnostic tools are 
usually unable to determine specific etiologies often diagnosing patients 
basted on clinical features.(1) Further confounding that is the fact that a 
majority of patients present with The management of AUFI based on 
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scientific rationale, logic, and prevalent clinical practices. Pretest probability 
of infectious diseases, severity of febrile illnesses availability of specific 
diagnostics, and response to drug therapy guide to the management. History 
and physical examination, the traditional tools used by health worker can 
provide important clues for the etiology of AUFI     
  
 Disease burden of infectious etiologies of acute febrile illness is under 
reported in various parts of India(24). 
     
 Syndrome based disease surveillance provides a useful methodology 
to systematically identify and document causes of acute fever. This 
approach has been used by European Network for Tropical Medicine(9) and 
Travel health, to diagnose fevers of Turkey(10), China(11) and India. 
     
 However, in Southeast Asian countries limited data exist on the 
etiologies of AFI in the India. It is important to maintain a proper 
epidemiological data of AFI so that evidence based diagnostic criteria and 
treatment guidelines can be developed (24). 
     
 Hence this study was undertaken to find out the etiology of AUFI and 
guide investigations and early treatment of adult patients presenting with 
fever to internal medicine department in a TERTIARY CARE HOSPITAL .  
  
Aims & Objectives 
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AIMS AND OBJECTIVES 
 
1. To study the etiology of Acute undifferentiated febrile illness among 
the fever patients 
2. To compare the laboratory parameters with clinical signs and 
symptoms 
 
  
Review of Literature 
  
5 
 
 
REVIEW OF LITERATURE 
    
 Acute undifferentiated fever (AUF) is a common cause of patients 
seeking healthcare in India, especially between June and September(27). 
Unlike fever of unknown origin (FUO), which enjoys a standard definition, 
AUF, also known as “acute febrile illness”, “short febrile illness”, or “acute 
fever” lacks an international consensus definition. Since FUO requires 
duration of fever to be longer than 3 weeks, some authors have defined 
AUFI as fever that resolves within 3 weeks. More traditionally however, 
AUF has been defined as fever of 2 weeks or shorter in duration(12). Thus the 
term AUF is used to denote fevers that typically do not extend beyond a 
fortnight, and lack localizable or organ specific clinical features. AUF poses 
a diagnostic and therapeutic challenge to the health workers, particularly in 
limited resource setting(14,15). A number of  viruses, bacteria, protozoa and 
rickettsiae can cause FUO. The non-specificity of symptoms and signs and 
lack of availability of accurate diagnostics not only test the clinical mettle of 
even astute physicians but often leads to irrational use of antibiotics and 
anti-malarials(5). These syndromes have better developed guidelines for their 
management. On the other hand, AUF-syndromes (such as fever-rash, fever-
myalgia, fever-arthralgia, fever-hemorrhage and fever-jaundice) have 
overlapping etiologies, which makes their diagnosis and management even 
more challenging. Fevers with proven diagnosis are known as diagnosed-
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AUFIs; those that diagnosis are called undiagnosed undifferentiated fevers 
UUF(6). Many UUFs often resolve either on their own or in response to 
empiric therapies. Diagnosis of many etiologies of AUF in the tropics can 
be established with help of simple tests, such as peripheral smear 
examination or rapid diagnostic tests (RDTs) for malaria or dengue. Some 
other etiologies need more sophiscated tests such as ELISA for rickettsial 
infections, MAT or ELISA for leptosporosis(5). Studies that have assessed 
the cause of AUF in Asia have indicated that depending on the nature of 
available laboratory support, between a quarter and half of AUFs may 
remain undiagnosed(14). 
    
 Febrile illness can be localized to organ systems or non-localized. 
There is a paucity of literature on the appropriate evaluation of adult fever 
patients without localizing symptoms in the emergency medicine 
department(6). Acute febrile illness (AFI), the initial diagnosis of whose 
cause is often presumptive, can sometimes be a challenge for the treating 
physician. A definite seasonal trend is observed with a peak in incidence 
with the arrival of the monsoon(13). 
    
 So public awareness regarding fevers in the pre-monsoon season 
should be done. Special care should be given to the elderly as they are often 
the most vulnerable. 
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Types of  Fever: 
Fever is generally classified clinically under the following types: 
 Continuous fever – Temperature remains above normal throughout 
the day and does not fluctuate more than 1 deg c in 24 hours e.g. lobar 
pneumonia, typhoid, meningitis, urinary tract infection, brucellosis & 
typhus. Typhoid fever may show a specific fever pattern with a slow 
stepwise increase and a high plateau. 
 Intermittent fever – The temperature elevation is present only for a 
certain period, later cycling back to normal, e.g. malaria, kala-azar, 
pyaemia, or septicaemia. 
 
Following are its types: 
1) Quotidian fever, with a periodicity of 24 hours, typical of 
Plasmodium falciparum or Plasmodium knowelesi malaria. 
2) Tertian fever (48-hour periodicity), typical of Plasmodium vivax or 
Plasmodium ovale malaria. 
3) Quartan fever (72-hours periodicity), typical of Plasmodium malariae 
malaria. 
4) Remittent fever: Temperature remains above normal throughout the 
day and fluctuates more than 1 deg c in 24 hours, e.g., infective 
endocarditis.(47) 
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SPECIAL TYPES OF FEVER 
1. Fever with rigors: This occurs in: 
 Malaria 
 Kala azar 
 Filariasis 
 Urinary tract infection 
 Cholangitis 
 Septicemia 
 Infective endocarditis 
 
2. Fever with herpes labialis: Elevated body temperature may activate the 
herpes simplex virus and cause small vesicles around the angle of the 
mouth (herpes labialis). It occurs with: 
 Pneumonia 
 Malaria 
 Meningitis 
 Streptococcal infection 
 
3. Fever with rash: This is seen in: 
 Chicken pox 
 Small pox 
 Measles 
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 Rubella 
 Typhus 
 Allergy 
 
4. Fever with membrane in the throat: occurs in: 
 Diphtheria 
 Infectious mononucleosis 
 Agranulocytosis 
 Moniliasis 
 Vincent’s angina. 
 
5. Fever with delirium: This is common in: 
 Encephalitis  
 Typhoid state 
 Meningitis  
 Pneumonia (47) 
 
Pathogenesis: 
 Fever appears to have evolved on vertebrate hosts as an adaptive 
mechanism for controlling infection. This phenomenon is produced by 
certain exogenous (largely microbial) stimuli that activate bone-marrow-
derived phagocytes to release a fever-inducing hormone (endogenous 
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pyrogen). Endogenous pyrogen, in turn, circulates to the thermoregulatory  
center of the brain (pre-optic area of the anterior hypothalamus) where it 
causes an elevation in the “set-point” for normal body temperature. Warm 
blooded animals produce fever by increasing heat production (through 
shivering) or reducing heat loss (by peripheral vasoconstriction), whereas 
cold blooded animals do so only by behavioural mechanisms (seeking a 
warmer environment). 
    
 Temperature is ultimately regulated in the hypothalamus. A trigger of 
the fever, called a pyrogen, causes a release of prostaglandin E2 (PGE2). 
PGE2 then in turn acts on the hypothalamus, which generates a systemic 
response back to the rest of the body, causing heat-creating effects to match 
a new temperature level. 
   
 In many respects, the hypothalamus works like a thermostat. When 
the set point is raised, the body increases its temperature through both active 
generation of heat and retention of heat. Peripheral vasoconstriction both 
reduces heat loss through the skin and causes the person to feel cold. If these 
measures are insufficient to make the blood temperature in the brain match 
the new set point in the hypothalamus, then shivering begins in order to use 
muscle movements to produce more heat. When the hypothalamic set point 
moves back to baseline either spontaneously or with medication, the reverse 
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of these processes (vasodilatation, and of shivering and non-shivering heat 
production) and sweating are used to cool the body to the new, lower 
setting. 
 
CAUSATIVE AGENTS: 
 AUFI generally has several etiological factors. Few pathogens that 
are suspected to be etiological agents of AUFI are.  
 
1. MALARIA: 
Definition (37,47) 
 Malaria is a protozoal disease caused by infection with parasites of 
genus. Plasmodium and transmitted to man by certain species of infected 
female anopheline mosquito. 
 
There are three stages:- 
- Cold stage 
- Hot stage 
- Sweating stage. 
 
Epidemiology: (51) 
Malaria in priority areas 
- Forests 
- Forested food hills 
- Forest fring areas 
- Development of project areas 
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1. Tribal malaria 
2. Rural malaria 
3. Urban malaria 
4. Border malaria. 
a) Plasmodium vivax causes benign tertian malaria 
b) Plasmodium falciparum causes malignant tertian malaria  
c) Plasmodium malariae causes benign quartan malaria 
d) Plasmodium ovale causes tertian malaria.(66) 
 
Life Cycle: 
The malarial parasite posses its Life Cycle in two different hosts. 
1. In man: The parasite residing inside the liver cell and Red Blood 
Corpuscle reproduces by asexual method (schizogony). Man represents 
intermediate host. 
2. In female anopheline mosquito: 
 The sexual forms (male and female gamatocytes) of cycle developed 
inside the human host. These are transformed to their insect host, where 
they develop further and transformed into sporozoites. These sporozoites are 
the infective to man. The mosquito represents the definitive host of the 
malarial parasite. 
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 Out of  45 species of anopheline mosquitoes in India, only few are as 
vector of primary importance.(16) 
 
Mode of transmission: 
 Men gets infection by the bite of female anopheles mosquito. 
Sporozoites from the salivary gland of the mosquito are directly introduced 
into the blood circulation. 
 
INCUBATION PERIOD: 
 P.vivax-8 days 
 P.falciparum-15 days 
 P. malariae-13 days 
 P. ovale-9 days 
 
Clinical features: 
COLD STAGE: 
 The onset is with lassitude, headache, nausea and chilly sensation 
followed in an hour or so by rigors. The temperature rises rapidly to  
39-41°C. Headache is often severe and commonly there is vomiting. In early 
part of this stage, skin feels cold; later it becomes hot. Parasites are usually 
demonstrable in the blood. The pulse is rapid and may be weak. This stage 
lasts for 1/4-1 hour. 
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HOT STAGE: 
 The patient feels burning hot and casts off his clothes. The skin is hot 
and dry to touch. Headache is intense but nausea commonly diminishes. The 
pulse is full and respiration rapid. This stage lasts for 2 to 6 hours. 
 
SWEATING STAGE: 
 Fever comes down with profuse sweating. The temperature drops 
rapidly to normal and skin is cool and moist. The pulse. Rate becomes 
slower, patient feels relieved and often falls asleep. This stage lasts for 2-4 
hours.(51) 
 
DIAGNOSIS: 
     The diagnosis of malaria depends on demonstration of the parasite in the 
blood. Suspicion of the diagnosis is aroused by epidemiological and clinical 
evidence. 
 
A. Two types of blood films are useful in searching for and identification 
of malaria parasite. The “thin film” and the “thick film”. It is 
recommended that both types of film be prepared on a single 
microscope glass slide. The thick film is more reliable in searching for 
parasite, as large volume of blood is examined under each microscope 
field. When scanty, parasite may be found about 20 times more rapidly 
in thick slide than in thin slide. The thin slide is more valuable for 
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identifying the species of the parasite present. In it they are seen more 
clearly(16). 
B. One step malaria antigen rapid test(43) 
 
TREATMENT(45,51) 
Uncomplicated malaria 
CHLOROQUINE 
Chloroquine base 
Day Children Adults 
Day 1 10mg/kg 600mg 
Day 2 10mg/kg 600mg 
Day 3 5mg/kg 300mg 
      
CHLOROQUINE TABLETS AS PER AGE GROUPS 
Chloroquinte   tablets 150 mg base 
Age in years Day 1 Day 2 Day 3 
<1 1\2 1\2 1\4 
1-4 1 1 1\2 
5-8 2 2 1 
9-14 3 3 1 1\2 
15 & above 4 4 2 
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PRIMAQUINE P. FALCIPARUMN (51) 
Primaquine single dose-day 1 
Age in years mg base No. of Tablets  (7.5 mg base) 
<1 Nil Nil 
1-4 7.5 1 
5-8 15 2 
9-14 30 4 
15 & above 45 6 
 
Malaria vaccines: (51) 
 Vaccine developed in Colombia (SPf66) advanced to phase III trials 
in Africa but failed to show efficacy in children under one year old, the 
highest risk group. Another vaccine (RTS, S/AS02) with the potential to 
prevent infection and/or ameliorate disease is being tested by 
GlaxoSmithKline and the MVI at PATH in Phase I trials in children in the 
Gambia. Beginning in 2002, Phase Ii trials of the vaccine are being 
conducted among children in Mozambique, which suffers from year-round 
malaria transmission-offering a better opportunity to evaluate vaccine 
performance (46). 
  
17 
 
 
2.  DENGUE(66) 
Definition:- 
 Dengue fever is zoonotic illness caused by viruses. Dengue viruses 
are arboviruses capable of infecting humans and causing disease. 
Arboviruses are group of ssRNA viruses. These infections may be 
asymptomatic or may lead to 
a) “classical” dengue fever 
b) Dengue haemorrhagic fever 
c) Dengue shock syndrome. 
 
Vectors: 
 Blood socking arthropods (Insect Vectors). Aedes aegupti is the 
principal vector. They bite during the day time. Aedes aegupti is nervous 
feeder and most efficient vector. Incubation period is 8-10 days. Once 
infected, it remains infective for life. Aedes can pass the dengue virus to the 
off spring by transovarial transmission. 
 
CLINICAL FEATURES AND DIAGNOSIS: 
a) Dengue fever (DF) 
b) Dengue haemorrhagic fever (DHF) 
c) Dengue shock syndrome (DSS) 
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CLINICAL DIAGNOSIS:  Of DHF without shock  
a) Fever – acute onset, high, continous and lasting 2 to 7 days. 
b) Haemorrhagic manifestations 
- Positive tourniquet test and 
- Petechiae, purpura, ecchymosis  
- Epitaxis, gum bleeding 
- Haematamesis/ melena. 
c) Hepatomegaly 
 
Grading of severity of  DHF (65) 
 Grade I : Fever accompanied by non-specific constitutional 
symptoms. Positive tourniquet test. 
 Grade II: Patient with spontaneous bleeding usually in the form of 
skin and other haemorrhages in addition the grade-I 
 Grade III: circulatory failure by rapid pulse and narrowing pulse 
pressure or hypotension with presence of cold clammy skin and 
restlessness. 
 Grade IV: Profound shock with undetectable blood pressure and 
pulse. 
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Laboratory diagnosis: 
 Thrombocytopenia (100,000/mm³ or less). There was a significant 
correlation of IgG titres with platelet counts, with higher titres associated 
with lower platelet counts. It is speculated that IgG, IgA and IgE produced 
in response to primary infections. 
- NS1 Antigen  
- IgM capture ELISA 
TREATMENT 
 The management of dengue fever is symptomatic and supportive. Bed 
rest is advisable during the acute febrile phase. Antipyretics or sponging are 
required to keep the body temperature below 40°C. The management of 
DHF during the febrile phase is similar to that of  DF> A rise in haematocrit 
value indicates significant plasma loss and a need for parenteral fluid 
therapy. Serial haematocrit determination, every four to six hours, and 
frequent recording of vital signs are recommended for adjusting the fluid 
replacement in order to assure adequate volume replacement and avoid over 
transfusion. 
  
 Crystelloid: five per cent dextrose in lactated Ringer’s solution, fiver 
per cent dextrose in acetated Ringer’s solution, five per cent dextrose in half 
strength normal saline solution and fiver per cent dextrose in normal saline 
solution. Colloidal: Dextran 40 and plasma.(49) 
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MANAGEMENT OF SHOCK: 
 DSS is a medical emergency that requires prompt and vigorous 
volume replacement therapy. There are also electrolyte (sodium) and acid-
base disturbances. It must be considered that there is a high potential for 
developing disseminated intravascular clotting (DIC) and that stagnant 
acidaemia blood will promote and/or  enhance DIC, which may lead to 
severe haemorrhage and/or irreversible shock (47,51). 
 
REPLACEMENT OF PLASMA LOSS: 
 Blood transfusion is indicated in cases with profound or persistent 
shock despite declining haematocrit values after initial fluid replacement. 
 
CONTROL MEASURES 
1. Mosquito control: 
 The vectors of DF and DHF (e.g., A. aegypti) breed in and around 
houses and, in principle can be controlled by individual and community 
action, using antiadult and antilarval measures. These measures are outlined. 
 
2. Vaccines: 
 So far, there is no satisfactory vaccine and no immediate prospect of 
preventing the disease by immunization. 
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3. CHIKUNGUNYA: 
Definition: 
 Chikungunya is a dengue – like disease caused by a group virus, and 
transmitted by the genus Aedes, culex, monsonia mosquitoes. 
 
Chikungunya virus belongs to 
 Family – togaviridae 
 Genus – Alpha virus 
 
 Based on clinical manifestations it can be catagorised into fever-
arthiritis group. Chikungunya fever is a re-emerging disease characterized 
by acute fever with arthalgia. 
 
Transmission: 
 Transmitted by Aedes aegupti mosquito which bite during day time. 
Rarely by vertical transmission from mother to fetus or by blood 
transfusion(16). 
 
CLINICAL FEATURES 
Incubation period 4-7 days  
- Sudden onset of fever, chills 
- Anorexia 
- Lumbago 
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- Conjunctivitis 
- Morbiliform rashes with purpura on the trunk and limbs 
 
Symptoms: 
- Coffee coloured vomiting 
- Epitaxis 
- Petechiae 
- Arthropathy- excruciating joint pains, swelling and stiffness 
especially in wrist, elbow, shoulder, knee ankle and metatarsal 
joints. It can be persists for months and even years. 
 
Diagnosis: 
 Virus can be isolated from the blood of febrile patients by the 
intracerebral inoculation in suckling mice or on VERO cells. 
 
Serdogical diagnosis: 
 ELISA is detected for IgM antibody. 
 
Treatment: 
 There is no specific treatment of chikungunya infection and it is 
usually self limiting. Analgesics, antipyretics like paracetamol, diclofenac 
sodium, chloroquine along with fluid supplementation are recommended to 
manage infection and relieve fever, joint pains and swelling (37,47). 
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CONTROL: 
Vector control(52) 
- Keep water storage free of mosquitoes and eliminate the other 
breeding places in and around the houses. 
- The organophospharous insecticide, Abate is used as a larvicide. 
- Anti adult measures can bring about a rapid interruption of 
transmission. 
- A new technique consisting of aerosol spray of ultra low-volume 
(ULU) quantities of malathion or sumithion is effective in 
stopping the transmission. (250ml/hectre) 
 
4. LEPTOSPIROSIS: 
 Leptospirosis is the most widespread of the disease transmited from 
animal to man. Out breaks occur due to season of heavy rain fall and 
consequent floodings(47,53-55). 
 
Epidemiology: 
AGENT FACTORS: 
 Leptospira are thin and light motile spirocheates 0.1-0.2µm wide and 
5-15 µm long with hooked ends. Leptospira interrogans are pathogenic. The 
organisms are visible by clark-field illumination and silver staining(17). 
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SOURCE OF RESERVOIRS: 
 Leptospirosis affects wild and domestic animals worldwide especially 
rodents such as rats, mice, and voles. (45) 
 
MODE OF TRANSMISSION: 
a) Direct contact 
b) Indirect contact 
c) Droplet infection 
 
INCUBATION PERIOD: 
 Usually 10 days with a range from 4-20 days. 
 
CLINICAL FEATURES: 
 Leptospirosis can manifest in many ways. The various syndromes of 
presentation are as follows: 
1. Anicteric leptospirosis 
2. Icteric leptospirosis (weil’s disease) 
3. Haemorrhagic fever with renal syndrome. 
4. A typical pneumonia syndrome. 
5. Myocarditis 
6. Ocular manifestations. (47) 
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INCUBATION PERIOD: 
     4 to 20 days. 
 
DIAGNOSIS: 
 IgM ELISA is useful in making an early diagnosis. 
 
CONTROL: 
Antibiotics: 
 Penicillin is the drug of choice but other antibiotic (tetracycline or 
doxycycline) are also effective. The dosage of penicillin 6 million units 
daily intravenously. 
 
Environmental factors: 
 Preventing the exposure contaminated water reducing the 
contamination by rodent control and protection of workers in hazardous 
occupation. Measures should be taken to control rodents proper disposable 
of wastes and health education. (53) 
 
Vaccination: 
 Vaccines are available. Immunization of farmers and pets prevent 
disease. Immunity to one type of leptospira may not protect against 
infection by another type(57). 
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5. SCRUB TYPHUS: 
 Scrub typhus is caused by orientia tsutsugamushi. It differs from 
rickettsiae genetically as well as by cell wall composition (It lacks of 
polysaccharide layer) (26). 
 
AGENT: 
 The causative agent of scrub typhus is Orientia  tsutsugamushi. 
 
Reservoir: 
The true reservoir of infection is the trombiculid mite. 
- Leptrombidium delinese 
- Leptrombidium akamushi  
- The nympal and adult stages of the mite are free living in the soil. 
- Chiggerosis: Among all stages of mite, the larva (chiggers) are the 
only stage that feed on humans. That is called chiggerosis. 
- Mites can maintain the organisms through transovarian 
transmission.(47) 
 
Mode of transmission: 
The mite of infected larval mites. The transmission cycle as below. 
Mite->Rats and mice->mite->Rats and mice 
The disease is not directly transmitted from person to person. 
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INCUBATION PERIOD: 
 10-12 days: varies 6-12 days. 
 
Clinical features: 
- Acute fever with chills (104°C-105°F) 
- Headache /myalgia 
- Malaise/cough 
- Prostration/GIT symptoms 
- Macular rash-5th day of illness. 
- Generalized lymphadenopathy and lymphocytosis(17) 
 
 Punched out ulcer covered with a blackened scab (eschar) which 
indicates the location of the mite bite. 
 
Laboratory test: 
- One step, scrub typhus Antibody test(Immuno chromatographic 
test). 
Treatment: 
 Tetracycline is the drug of choice. (4) 
Control measures: 
 Cleaning the vegetation where rats and mite live. Application of 
insecticides such as lindane or chlordane to the ground . 
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- Personal prophylaxis. (51) 
 
 
6. TYPHOID FEVER: 
 Typhoid fever is the result of systemic infection mainly by salmonella 
typhoid found only in man. 
 
 The term “enteric fever” includes both typhoid and paratyphoid 
fevers. The disease may occur sporadically, epidemically or endemically(47). 
 
AGENT FACTORS: 
 Salmonella typhi is the major cause of enteric fever. Salmonella 
paratyphi A, paratyphi B are relatively infrequent. Salmonella typhi has 
three main antigen –o, H, and vi. 
 
RESERVOIR OF INFECTION: 
Man is the only known reservoir of infection through cases and carriers. 
(i) Cases may be mild or severe carrier is infectious as long as bacilli 
appear in stool or urine. 
(ii) CARRIERS: The carriers may be temporary or chronic. 
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Clinical features 
 The classic presentation includes fever, malaise, diffuse abdominal 
pain, and constipation. Untreated, typhoid fever is a grueling illness that 
may progress to delirium, obtundation, intestinal hemorrhage, bowel 
perforation, and death within 1 month of onset. Survivors may be left with 
long-term or permanent neuropsychiatric complications(58). 
 
 Typhi has been a major human pathogen for thousands of years, 
thriving in conditions of poor sanitation, crowding, and social chaos. In the 
advanced stages of typhoid fever, the patient’s level of consciousness is 
truly clouded. Although antibiotics have markedly reduced the frequency of 
typhoid fever in the developed world, it remains endemic in developing 
countries(59). 
 
INCUBATION PERIOD: 10-14 days. 
 
MODE OF TRANSMISSION: 
 Typhoid fever transmitted through the faecal-oral roate or urine-oral 
route. 
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TREATMENT(47): 
 Drug of choice Alternate drugs 
Emperical Treatment 
This is the treatment 
given before 
antimicrobial 
susceptibility report is 
available. 
Ceftriaxone 
 
 
 
 
Azithromycin. 
Fully susceptible  Ciprofloxacin 
Amoxycillin 
chloramphenical 
cotrimoxozole 
MDR strains (multidrug 
resistant) 
Ciprofloxacin 
Ceftriaxone 
Azithromycin. 
NAR strains 
(NALIDIXIC acid 
resistant) 
Ceftriaxone 
Azithromycin. 
Ciprofloxacin 
Carriers 
Ampicillin or  
Amoxycillin probenecid 
for 6 weeks 
Cotrimoxozole or 
Ciprofloxacin. 
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CONTROL OF TYPHOID FEVER: 
There are three methods of defence against typhoid fever. 
a) Control of reservoir 
b) Control of sanitation 
c) Immunization(47,60) 
 
VACCINE: 
1.   Parentral TAB vaccine. 
2. Parentral V1 polysaccaride vaccine 
3. Typhoid (oral live attenucated s. TyphiiTyz  Ia Vaccine (47,55,58) 
 
DIAGNOSIS OF FEVER: 
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MATERIALS AND METHODS 
 
Place of study: 
 Institute of Microbiology & Institute of Internal Medicine, 
 Rajiv Gandhi Government General Hospital (RGGGH), 
 Chennai – 03. 
 
Study design: 
 Prospective study. 
 
Study period: 
 One year. 
 
Sample size: 
 150 patients presented with AUFI admitted in a tertiary care hospital. 
 
Ethical consideration: 
 All patients detail, satisfying the following inclusion criteria will be 
documented and taken up for the study after obtaining informed written 
concern in both regional language and English. This study was reviewed by 
Institutional Ethics Committee and clearance number obtained.  
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Inclusion criteria: 
 Adult patients of more than 18 years of age 
 Patients with acute fever less than 14 days duration with body 
temperature of more than 38 deg C who are admitted in the hospital. 
 The cause of illness undiagnosed after medical history and physical 
examination. 
 
Exclusion criteria: 
 Patients aged less than 18 years. 
 Fever more than 14 days 
 Patient with clinical systemic involvement. 
 Patient with coexisting infections. 
 
BLOOD CULTURE: 
Sample collection and processing: 
 Under strict aseptic precautions, venipuncture site was cleared with 
70% alcohol and then with 2% poidane Iodine(61). The disinfectant was 
allowed to act for 1 minute and then 10ml of blood sample was collected 
with a sterile syringe and added into a sterile crew capped blood culture 
bottle containing 50ml of sterile Brain heart infusion broth (BHI) broth.  
(1:5 dilution) and was labeled with name, age, sex, IP No date and time of 
collection and culture bottles transported immediately to the laboratory(21). 
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Sample processing: 
 The culture bottles were incubated at 37°C for 24 hours. Observe for 
turbidity, pellicle formation and deposits, the subcultures made on to the 
following plates using sterile techniques(18). 
 
Interpretation 
 All inoculated plates were observed for growth after 24 hours. The 
colony size, shape, edge, margin and consistency was noted. 
 
Subculture was done on NAP, MAC, 5% sheep blood agar plate.  
 
NAP – colonies on these media are 2-3mm in diameter, greyish white, 
circular, moist, convex and translucent colonies, opaque and granular 
colonies with irregular surface. 
BAP – Non hemolytic moist colonies. 
MAC – colonies are round (1-3mm size) translucent, pale and non-lactose 
fermenting. 
 
Biochemical identification of Salmonellae: 
 Catalase - positive and oxidase – negative 
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ICUT test: 
 Indole  – Negative 
 Citrate  – Positive – salmonella paratyphi-B  
  Negative  – Salmonella Typhi and salmonella paratyphi – A. 
 Urease  – Negative 
Triple sugar iron test 
 Alkaline / acid 
 Gas present (Salmonella typhi – No gas present) 
 Abundant H2S present – salmonella paratyphi B salmonella Typhi 
speck of H2S present at the junction of slant and butt. 
 MR positive and VP negative. 
 
Decarboxylation test(LAO): 
 Salmonella Typhi – only lysine is decarboxylated 
 Salmonella paratyphi A – only ornithine 
 Salmonella paratyphi B – positive for all (21). 
 
Antimicrobial susceptibility Testing: 
 Antibiogram was done on Mueller-Hinton agar by disk diffusion 
method. 
 Antibiotic Sensitivity pattern. As per CLSI Guidelines (21). 26th 
Edition, M100S 
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Drugs Disc content 
Sensitive 
(mm) 
Intermediate 
Sensitive 
(mm) 
Resistance 
(mm) 
Ampicillin 10 µg ≥ 17 14-16 ≤ 13 
Cotrimoxazole 
(Tmp/smz) 1.25/23.75 ≥ 16 11-15 ≤ 10 
Chloramphenical 30 µg ≥ 18 13-17 ≤ 12 
Ceftrioxone 30 µg ≥ 23 20-22 ≤ 19 
Nalidixic acid 30 µg > 19 14-18 ≤ 13 
Pefloxacin 5µg ≥ 24 13-15 ≤ 23 
Azithromycin 15µg ≥ 13 - ≤ 12 
Cefotoxime 30µg ≥ 26 23-25 ≤ 22 
 
 Antimicrobial Susceptibility pattern of S.Typhi by disc diffusion 
method (63). 
Organism AMPI 10g 
COT 
1.25 / 
23.75g 
CK 
30g 
CTX 
30g 
CFT 
30g 
AZIT 
15g 
NA 
30g 
PEF 
5g 
S.Typhi 
(n=5) 100% 100% 100% 100% 100% 100% 0 0 
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 Ciprofloxacin has remained the drug of choice of enteric fever for last 
many years. However, isolates of S.Typhi with reduced susceptibility for 
fluoroquinolones have been appeared in the subcontinent, Vietnam, 
Tajikistan and the treatment failures with fluoroquinolones has also been 
noted. 
 
 In vivo adaptive mutations have been reported to occur on continuous 
sub-inhibitory exposure to Ciprofloxacin. Also the frequent use of 
Pefloxacin for trivial infections is likely to promote resistance to these 
agents. 
 
PERIPHERAL SMEAR: 
 The pulp of a finger of the patient was wiped with alcohol & allowed 
to dry. Then it was picked with surgical cutting needle and two drops of 
blood was taken on a grease free clean glass slide, one half an inch the right 
end of the slide. The former was made into a thick film and later into a thin 
film. The drop for thick film was spread with a needle to form an area on 
half an inch square. Through this film a news paper print should be read. 
The film should be prepared by folding a spreader at smooth edge of glass 
slide an angle of 45° in contact with the drop of blood, then lowered to an 
angle of  30° and pushed gently to the left till the blood is exhausted to form 
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tail. The film is allowed to air dry. The thick film is dehaemoglobinised by 
placing in a glass cylinder with distilled water in a vertical position for 5 to 
10 mins. When the film becomes white it was taken out and allowed to dry 
on upright position. Undiluted Leishman ‘s stain and after dilution on the 
stain is poured over the thin film is flooded over the thick film. The stain 
was allowed remain on the slide for 10 to 15 mints. The slide was washed 
with running tap water and allowed to dry on upright position. Then it was 
examined under oil immersion lens(16). 
 
SEROLOGICAL TEST: 
 Blood was collected by aseptic technique. Prior to venipuncture, the 
skin must be decontaminated with 2% chlorohexidine or 70% alcoholic rub 
by making a smooth circular pass over the site and moved in an outward 
spiral from the zone of penetration. The skin was allowed to dry before 
processing. For each patient about 5ml of blood sample was collected by 
venipuncture by a disposable sterile syringe and transferred to a sterile 
labeled test tube. Left to clot for 30mins and then centrifuged at 3000x8 
from which the serum was separated, aliquoted and preserved at -70°c(16). 
 
DENGUE  NS1  ANTIGEN  CAPTURE ELISA: 
 Principle: Serum dengue NS1 antigen, when present, binds to anti-
Ns1 antibodies attached polystyrene surface of the microwells. Residual 
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serum is removed by washing, and HRP conjugated Anti-NS1 MAb is 
added. After incubation, the microwells are washed and a colourless 
substrate system, tetramethylbenzidine\hydrogen peroxide (TMB 
chromogen) is added. The substrate is hydrolysed by the enzyme and the 
TMB changes to a blue colour. After stopping the reaction with the acid, the 
TMB turns yellow. Colour development is indicative of the presence of 
Dengue NS1 antigen in the test sample. 
 
 Test procedure: The patients sample and all the reagents of the kit 
were brought to room temperature. The required microwells were removed 
from the foil sachet and inserted into the strip holder. Using suitable test 
tubes or a microtitre plate the Positive Control, Negative Control, Calibrator 
and patients sample were diluted. (75µl of sample diluents was added to 
75µl of sample and mixed well. The final dilution was 1 in 2. 
 
 100 µl of diluted test samples and controls (positive control, Negative 
control and Calibrator in triplicate) was pippetted into the respective 
microwells. 
 The plate was covered and incubated for one hour at 37°c. 
 Washed 6 times with diluted wash buffer. 
 100 µl of HRP conjugated Anti-NS1 MAb was pipette into each well. 
 The plate was covered and incubated for one hour at 37°c. 
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 Washed 6 times with diluted wash buffer. 
 100 µl of TMB pipette into each well. Incubated for 10 minutes at 
room temperature. A blue colour developed. 
 100 µl of stop solution was pipette into all wells in the same sequence 
and timing as the TMB addition and mixed well. The blue colour 
changed to yellow. 
 Within 30 minutes the absorbance of each well was read to a 
wavelength of 450nm with a reference filter of 600-650nm. 
 
QUALITY CONTROL: 
 Abs (a) 450nm  
 Calibrator factor  :  0.69 
 Negative Abs  :  >0.300 
 Cut off value  : ≥2.0 x neg Abs 
 Positive cut off ratio : 1:1 - 7.0 
 
CALCULATIONS: 
 The average absorbance of the calibrator triplicates was calculated 
and multiplied by calibration factor. This is the cut-off value. Index value 
was calculated by dividing the sample absorbance by cut-off value. 
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Interpretation of results: 
 If Index value <0.9 it is negative. 
 If Index value is 0.9-1.1 then it is equivocal. 
 If Index value is >1.1 it is positive. 
 
DENGUE IgM CAPTURE ELISA: 
 Principle: serum antibodies of the IgM class, when present binds to 
anti-human IgM antibodies attached to polystyrene surface of the microwell 
test strips. A concentrated pool of Dengue 1-4 antigens is diluted to correct 
working volume with antigen diluents. The antigens are produced using an 
insect cell expression system and immunopurified utilizing a specific 
monoclonal antibody. Anequal volume of the HRP conjugated MAb is 
added to the diluted antigen, which allows the formation of antigen-MAb 
complexes. Residual serum is removed from the assay plate by washing and 
complexed antigen MAb is added to the assay plate. After incubation, the 
microwells are washed and a colourless substrate system, 
tetramethylbenzidine / hydrogen peroxide (TMB chromogen) is added. The 
substrate is hydrolysed by the enzyme and the TMB changes to a blue 
colour. After stopping the reaction with the acid, the TMB turns yellow. 
Colour development is indicative of the presence of anti-dengue IgM 
antibodies in the test sample. 
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TEST PROCEDURE:  
 The patients sample and all the reagents of the kit were brought to 
room temperature. The required microwells were removed from. The foil 
sachet and inserted into the strip holder. Using suitable test tubes or a 
microtitre plate the positive control, negative control, calibrator and patients 
sample were diluted. (1000µl of sample diluents was added to 10µl of 
sample and mixed well. 
 
 The antigen was diluted to 1/250 using antigen diluents. 
 
 Required volume of diluted antigen was mixed gently with equal 
volume of MAb Tracer in a clean polypropylene vial and waited for 10 
minutes. 
 
 100µl of diluted test samples and controls (positive control, Negative 
control and Calibrator in triplicate) was pippetted into the respective 
microwells. 
 
 The plate was covered and incubated for one hour at 37°c. 
 Washed 6 times with diluted wash buffer. 
 100µl of mixed antigen-MAb tracer was pipette into each well. 
 The plate was covered and incubated for one hour at 37°c. 
 Washed 6 times with diluted wash buffer. 
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 100µl of TMB pipette into each well. Incubated for 10 minutes at 
room temperature. A blue colour developed. 
 100µl of stop solution was pipette into all wells in the same sequence 
and timing as the TMB addition and mixed well. The blue colour 
changed to yellow. 
 
 Within 30 minutes the absorbance of each well was read at a 
wavelength of 450nm with a reference filter of 600-650nm. 
 
QUALITY CONTROL: 
 Abs (a) 450nm  
 Calibrator factor  : 0.80 
 Negative Abs  :  >0.400 
 Cut off value  : ≥1.5xnegAbs 
 Positive cut off ratio : 1:1.9.0 
 
CALCULATIONS: 
 The average absorbance of the calibrator triplicates was calculated 
and multiplied by calibration factor. This is the cut-off value. 
 
 Index value was calculated by dividing the sample absorbance by cut-
off value. 
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Interpretation of results: 
 If Index value < 0.9 it is negative. 
 If Index value is 0.9-1.1 then it is equivocal. 
 If Index value is >1.1 it is positive. 
 
CHIKUNGUNYA IgM CAPTURE ELISA: 
 Procedure: Serum was diluted1:!00 in deep well plate using sample 
diluents for CHIK IgM 
 
 Required number of anti IgM coated strips was removed from the 
pouch. 
 
 The strips was washed 3 times with 1x wash buffer and the wells 
were not allowed to dry. 
 
 50µl of the diluted samples were transferred  from the deep well plate 
to respective wells as per the protocol on ELISA sheet using multichannel 
pipette. 
 
Add 50µl of CHIK IgM Positive control and CHIK IgM negative 
control to respective wells .(The controls were not diluted) 
 
 The plate was covered with aluminium foil and incubated at 37⁰C for 
one hour. 
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 The plate was then washed five times with 1x wash buffer.To remove  
traces of wash buffer content the plate was tapped on a tissue paper after last 
wash. 
 
 50µl of CHIK antigen was added to each well of the plate. 
 
 Again the plate was covered with aluminium foil and incubated at 
37⁰C for one hour. 
 
 The plate was then washed five times with 1x wash buffer.To remove  
traces of wash buffer content the plate was tapped on a tissue paper after last 
wash. 
 
 50µl of Anti CHIK MAbHxB(Biotin labeled ) was added to each 
well. 
 Then it was incubated and washed as before. 
 50µl of Avidin-HRP  was added to each well. 
 The plate was covered with aluminium foil and incubated at 37⁰C for 
30 minutes. 
 Washed 5 times with1x wash buffer as before. 
 100µl of Liquid TMB Substrate (TM/H2O2) was added to each well. 
 Incubated at room temperature in dark for 10 minutes. 
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 The reaction was stopped after 10 minutes with addition of 100µl of 
stop solution. 
 The absorbance was measured at 450 n as early as possible. 
 
QUALITY CONTROL: 
1. If OD of negative control is more than0.18 or 
2. If OD of positive control is less than 6 times the OD of negative 
control. 
 
 In both the situations, the test should be considered as invalid. 
 
Interpretation of Results:   
1. Sample OD ≤ Negative control x 2.0 - sample should be considered as 
negative 
2. Sample OD ≥ Negative control x 3.0 - sample should be considered as 
positive 
3. Sample OD ≥ Negative control x 2.0 but less than Sample OD ≤ 
Negative control x 3.0-sample should be considered as equivocal. 
 
MSAT (Macroscopic Slide Agglutination Test): 
 Principle: Slide agglutination test using formalinised and heat killed 
pooled antigen from leptospires belonging to different serovars commonly 
prevalent in and around Chennai. 
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Materials Required: 
 Prepared in-house leptospiral antigen 
 Cavity slide 
 Phosphate buffered saline(PBS) pH7.2 
 Test sera 
 Micropipette (range:5-50µl) 
 
Procedure: 
 One drop (12 µl) of antigenic substance was mixed with a drop of 
PBS(7 µl) and patients sera of about 6 µl on a depression slide and rotated 
on a rotator at 120 rpm for 8 minutes. It was examined macroscopically for 
the presence of agglutination and also confirmed using dark field 
microscope. Positive and negative controls were also put up. 
Interpretation: 
It was interpreted as follows: 
1 Clumps of agglutination with complete clearing of leptospiral antigen suspension 4+ 
2 Obvious agglutination but partial clearing of suspension 3+ 
3 50% agglutination 2+ 
4 25% agglutination 1+ 
5  No agglutination and uniformity of serum antigen mixture Negative 
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  A 2+ and above agglutination titre is indicative of recent infection 
and considered significant. 
 
ONE STEP SCRUB TYPHUS ANTIBODY TEST 
 The SD Bioline Tsutsugamushi test was developed using the major 
surface antigen 56 kDa of representative strains of Orentia tsutsugamushi 
(Karp, Kato and Gilliam).It is solid phase, immunochromatographic assay 
for the rapid qualitative detection of IgG,IgM or IgA antibodies to 
O.tsutsugamushi in human serum,plasma or whole blood. 
 
Principle:  
 This test has  2 pre-coated lines on the surface of the 
strip.”T(O.tsutsugamushi antibody test line )and “C”(control line.The 
control line is used for procedural control and should always appear if the 
test procedure is performed properly and the test reagents of the control line 
are working.A purple “T “line will be visible in the result window if there 
are enough IgG,IgM or IgA O.tsutsugamushi antibodies in the specimen.If 
IgG,IgM or IgA antibodies to O.tsutsugamushi are not present in the 
specimen,no colored “T“line will appear. 
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Procedure: 
 All the kit components and the specimens were brought to room 
temperature prior to testing. 
 
 The test device was removed from the pouch and kept on a flat,dry 
surface. 
 
 10µl of serum was slowly dispensed  to the specimen well (S) and 
then 3-4 drps of assay diluents was dispensed. 
 
 As the test begins to work the purple color moved across the result 
window in the centre of the device. 
 
 The test was interpretated at 10-15 minutes. 
 
Interpretation: 
 A colored control line will appear in the left section of the result 
window to show that the test is working properly. 
 
 Negative result: The presence of only the control line  “C” within the 
result window indicates a negative result. 
 
 Positive result: The presence of both the “C”and “T” line within the 
result window indicates a positive result. 
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 Invalid result : If the “C” line is not visible within the result window 
after performing the test, the result is considered invalid. 
 
ONE STEP MALARIA ANTIGEN RAPID TEST 
 The whole blood of 2ml  was collected by venipuncture under strict 
aseptic precaution into the collection tube containing EDTA.If the test was 
delayed the sample was refrigerated at 2-8◦C for not more than 3 days. 
 
 Alere TruelineTM Rapid Test Kit for Malarial Ag P.f/P.(HRP-
II/pLDH) Test is a one step,rapid qualitative and differential test for the 
detection of Histidine Rich Protein-II specific to Plasmodium falciparum 
and Plasmodium Lactate Dehydrogenase pan specific to Plasmodium 
species in human blood specimen. 
 
Principle  of the Test: 
 This test cassette contains a membrane strip which is precoated with 
one monoclonal antibody and one polyclonal antibody as two separate lines 
across a test strip.One monoclonal antibody (test line P.f) is specific to 
HRP-II of p.falciparum and other polyclonal antibodies (test line pan) are 
pan specific to the LDH of Plasmodium species (P.vivax, P.malariae, 
P.ovale).The test device has “Test lines”(P.f and Pan ) and “Control line”on 
the surface of the device. 
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Procedure: 
 The specimen and kit components are brought to room temperature 
prior to testing. 
 
 The test device was removed from the pouch and kept on a flat, dry 
surface. 
 
 5µl of blood specimen was carefully placed into the round sample 
well using a disposable specimen loop provided. 
 
 4 drops of assay diluents was added into the square assay diluent 
well. 
 
 Test results was interpreted within 20-30 minutes. 
 
Interpretation of the results: 
 Negative result:The presence of only the control line  “C” within the 
result window indicates a negative result. 
 
 P.falciparum Positive:The presence of  two color bands (“P.f” Test 
line and “C”control line) or three color bands(“P.f”,”Pan” Test lines and 
“C”control line) within the result window indicates a positive result. 
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 Other Plasmodium species (P.v,P.m,P.o)positive: The presence of  
two color bands (“Pan” Test line and “C”control line) within the result 
window indicates other plasmodium species positive result. 
 
 Mixed infection:P.f and P.v (or P.m,P.o): The presence of  three color 
bands(“P.f”,”Pan” Test lines and “C”control line) within the result window  
may indicate a  mixed infection. 
 
 Invalid result: If the “C” line is not visible within the result window 
after performing the test, the result is considered invalid. 
 
WIDAL TEST 
 Principle of the test: The organisms causing enteric fever possess two 
major antigens namely somatic 'O'antigen and flagellar 'H' antigen.During 
infection antibodies are produced in patients sera against these 'O' and 'H' 
antigens. Widal test detects the amount of antibodies formed in the patients 
serum. 
 
Method: 
 Master dilution of the patients serum was prepared in a test tube of 
12x100 mm. 0-2. 2.3 ml of saline (0.85% Sodium chloride) was added to 
0.2 ml of patients serum.This gave 1:12.5 dilution. Then a test tube rack 
55 
 
 
having 8-10 holes in 4 rows each was taken. 7 test tubes was kept in each 
row and labelled as(l) TO (2)TH (3)AH and (4) BH. 
 
 From the master dilution,0.2ml was added into the first and second 
tube in all rows of tubes T0,TH,AH and BH. 
 
 0.2ml of saline was added into all tubes from 2-7 in all rows including 
the controls (7th tube). The dilution of the serum was carried out as 
follows.0.2ml was mixed and transferred from tube 2 to 3,then from 3 to 4 
and so on ,through tube 6.0.2ml was discarded from tube 6. 
 
 The same dilution was followed for TH,AH and BH rows. For the 
rows 'TO'/TH', 'AH', 'BH' 0.2 ml of corresponding 'TO'/TH', 'AH', 'BH' 
antigen was added into 1-7 tubes of respective rows. The final dilution 
obtained was l:25,l:50,l:100,l:200,l:400,l:800.Tube 7 in each row was a 
negative antigen control. 
 
 For positive control same dilutions was proceeded with TO, T, H 
positive serum. 
 
 The rack was incubated at 37°C for 18-24 hours and the results were 
read as follows. "H"Agglutination -formation of loose, cotton wooly 
clumps. "O"Agglutination-granular matt like spread at the bottom of the 
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tube. Controls with no agglutination was seen as compact button of settled 
organisms. 
 
 The last tube showing the agglutination was taken as the end point. 
The reciprocal of that dilution was taken as the titre. 
 
 100 l of mixed antigen - MAb tracer was pipette into each well. The 
plate was covered and incubated for one hour at 37°c. Washed 6 times with 
diluted wash buffer. 
 100l of TMB pipette into each well. Incubated for 10 minutes at 
room temperature. A blue colour developed. 
 
 1001 of stop solution was pipette into all wells in the same sequence 
and timing as the TMB addition and mixed well. The blue colour changed to 
yellow. 
 
 Within 30 minutes the absorbance of each well was read at a 
wavelength of 450nm with a reference filter of 600-650nm. 
 
QUALITY CONTROL: 
 Abs (a) 450nm 
 Calibrator factor  : 0.80 
 Negative Abs  : >0.400 
57 
 
 
 Cut off value  :  >1.5xnegAbs 
 Positive cut off ratio :      1:1.9.0 
 
CALCULATIONS: 
 The average absorbance of the calibrator triplicates was calculated 
and multiplied by calibration factor. This is the cut-off value. 
 
 Index value was calculated by dividing the sample absorbance by cut-
off value. 
 
Interpretation of results: 
 If Index value < 0.9 it is negative. 
 If Index value is 0.9-1.1 then it is equivocal. 
 If Index value is >1.1 it is positive  
  
Results 
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RESULTS 
 
 Blood samples were collected from 150 patients who were clinically 
suspected to have no other definite sources of infections identified such as 
pneumonia, acute infectious diarrhea, UTI, smear positive pulmonary 
Tuberculosis, skin and soft tissue infections except fever as the main 
symptom. The samples collected and processed in microbiology laboratory. 
The results were analysed and tabulated as follows 
 
Table-1 : AGE WISE DISTRIBUTION (n=150) 
Age (Years) Number Percentage 
18-30 82 54.7% 
31-40 33 22% 
41-50 18 12% 
51-60 6 4% 
61-70 10 6.7% 
71-80 1 6% 
Total 150 100% 
 
AUFI most commonly presenting age groups are in between the 18-30 years 
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Table – 2 : GENDER WISE DISTRIBUTION (n=150) 
 
Sex Number Percentage 
Male 85 57% 
Female 65 43% 
Total 150 100% 
 
 The males are more commonly affected by AUFI than females. Males 
are highly exposed to the environmental pathogens. Male -57%, Female -
43%. 
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Table-3 : MONTH WISE DISTRIBUTION OF CASES 
Month 
2016 
Blood 
Culture 
(5) 
PS 
(9) 
Malaria 
RDT  
(6) 
Dengue Chikun 
gunya  
(IgM) 
(6) 
Lepto 
(31) 
Widal 
Test 
(9) 
Scrub 
Typhus 
IgM 
(8) 
NS1 
(17) 
IgM 
(23) 
April - - - -  - - - - 
May - - - -  - - - - 
June - 1 - -  - - - - 
July - 1 - -  - - - - 
Aug - - - 2 2 - 3 - - 
Sep 2 1 1 7 10 1 5 2 2 
Oct 2 1 1 8 4 3 8 1 1 
Nov 1 1 2 - 2 2 9 3 2 
Dec - 1 - - 2 - 3 2 2 
2017 - - - - - - - - - 
Jan - 1 2 3 2 - 3 1 1 
Feb - 1 - 1 1 - - - - 
March - 1 - -  - - - - 
 5 9 6 17 23 6 31 9 8 
Male
57%
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43%
GENDER WISE DISTRIBUTION
Male
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 AUFI cases more higher in the month of  
September to December 
 
MONTH WISE DISTRIBUTION OF CASES 
  
0 2 4 6 8 10 12
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July
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Jan
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Scrub Typhus IgM Widal Lepto
Chikungunya IgM Dengue IgM Dengue NS1
Malaria RDT PS Blood Culture
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Table-4 : DURATION OF FEVER (n=150) 
Days Number Percentage 
5-10 days 141 94% 
11-14 days 9 6% 
Total 150 100% 
 
 Fever 5-10 days of duration was higher incidence (94%), 10-14 days 
of fever cases lower (6%). 
 
 
  
94%
6%
DURATION OF FEVER
5-10 days
11-14 days
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Table-5 : ETIOLOGICAL CLASSIFICATION OF AUFI (n=150) 
SI. 
No Laboratory Investigations 
Number of 
Positive Percentage 
1 Blood culture 5 3.3% 
2 Malaria 
Peripheral blood smear 9 
6% One step malaria Antigen Rapid test 6 
Both positive (a&b) 6 
3 Dengue by Elisa 
NSI Antigen 17 11% 
IgM Elisa 23 15.3% 
Both positive (a&b) 10  
4 Chikungunya 6 4% 
5 Macroscopic slide agglutination test for leptospirosis 31 21% 
6 Widal test for enteric fever 9 6% 
7 Scrub typhus Rapid card test 8 5% 
8 Unclassified 42 28% 
 
 According to the basis of Etiological classification of AUFI, the 150 
samples tested, 40(26.6%) were positive for dengue, 31(21%) for 
leptospirosis, for malaria 9(6%), for enteric fever 9(6%), for scrub typhus 
8(5%), for chikungunya 6(4%), for blood culture for salmonella 5(3.3%), In 
42(28%) cases the etiology was unknown. These data are depicted in table. 
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Table-6 : LABORATORY PARAMETERS 
       
 Malaria Dengue Chikun gunya 
Leptos 
pirosis Typhoid 
Scrub 
Typhus 
Anaemia 9 - - - - - 
Leucopenia - 18 6 - 9  
Leucocytosis - - - - - - 
Thromobocytopenia 3 32 - - - - 
Bilirubin - 2 - 27 - - 
Urine albumin - - - 5 - - 
SGOT - - - 13 - - 
SGPT - - - 26 - - 
 
 150 Samples were tested. Anemia 9(6%), Leucopenia 18(12% )    
Thrombocytopenia 32(21.3%), Bilirubin 29(19.3%), Urine albumin 
5(3.3%), SGOT 13(8.6%), SGPT 26(17.3%).  
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Table-7 : CLINICAL FEATURES 
 
Clinical Features Number Percentage 
Fever with Rigor & Chills 126 84% 
Headache 44 29% 
Nausea/vomiting 80 53% 
Joint Pain 6 4% 
Cough/Dyspnea 13 9% 
Diarrhea/Loose stools 21 14% 
Calf mules tenderness 11 7% 
Eschar 6 4% 
Rash 7 5% 
Arthalgia 7 5% 
Altered sensorium 6 4% 
Abdominal Pain 43 29% 
Bleeding Manifestation 18 12% 
Hematamesis 23 15% 
Retro orbital pain 6 4% 
 
 84% of the patients presented with complaints of fever with rigor and 
chills followed with 53% with nausea and vomiting 29% with headache and 
29% with abdominal pain. 
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Table-8 : AGE WISE DISTRIBUTION OF CAUSES OF AUFI 
 
Total  Number of  Cases – 150 
Total  Number of  Positive Cases  (n=108) 
AGE 
(Years) Malaria 
Dengue 
NS1 
An 
Dengue   
IgM 
Elisa 
Chikun 
gunya 
(6) 
Lepto 
(31) 
Widal  
(9) 
Scrub 
Typhus 
(8) 
Blood 
Culture 
(5) 
18-30 4 10 15 5 15 4 7 2 
31-40 2 3 6 - 8 2 - - 
41-50 1 1 2 1 - 2 - 2 
51-60 - - - - - - - - 
61-70 2 3 - - 1 1 - 1 
71-80 - - - - - - 1 - 
 9 17 23 6 31 9 8 5 
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Table-9 : CLINICAL MANIFESTATIONS OF DENGUE  
 
Fever Rashes Vomiting Headache Bleeding Manifestation 
40 11 14 34 10 
100% 28% 35% 85% 25% 
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Table-10 : DEFECTION OF MALARIA AMONG AUFI  PATIENTS 
(n=9) 
 
Tests Number of positives Percentage 
Peripheral blood smear 9 6% 
One Step Malaria Antigen rapid  test 6  
Both positive a&b 6  
 
   
0
1
2
3
4
5
6
7
8
9
Peripheral blood
smear
One Step Malaria
Antigen rapid  test
Both positive a&b
9
6 6
DEFECTION OF MALARIA AMONG AUFI  PATIENTS
72 
 
 
Table-11 : CLINICAL MANIFESTATIONS OF LEPTOSPIROSIS 
Total  Number of  Cases – 150 
Total  Number of  Positive Cases (n=31) 
S. 
No Presenting Complaints Numbers Percentage 
1 Fever 29 19% 
2 Headache 22 15% 
3 Malaise 22 15% 
4 Jaundice 27 18% 
5 Abdominal Pain 23 15% 
6 Albumin Urine 5 3.3% 
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DISCUSSION 
 
 Fever is the main clinical symptom of various tropical infectious 
diseases. The etiologies of human febrile illness can vary region wise in 
India suggesting that diagnosis, treatment and control programs need to be 
based on a methodical evaluation of area specific etiologies. Common 
causes of undifferentiated febrile illnesses  include dengue, malaria, 
leptospirosis, enteric fever, chikungunya and rickettsiae. Reliable 
laboratory-confirmed diagnosis of AFI require a positive bacteriological \ 
serological test such as culture results and serological confirmation & 
pathogen specific antibodies (Immunoglobulin IgM) (or) a four-fold rise in 
IgG. 
 
 This prospective sectional study was conducted in the Institute of 
Microbiology, Institute of Internal medicine. Rajiv Gandhi Government 
General Hospital, Chennai during the period of September 2016 - August 
2017. The present study includes 150 patients presented with AUFI. 
 
 In the present study, among 150 patients with acute febrile illness 85 
were male (57%) and 65 were female (43%). And most commonly affected 
age group were from 18-30 yrs (54.7%) followed by 31-40 yrs(22%). This 
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was similar to study conducted by Das et al 2015 where  male (56%) and 
female (43%) and commonly affected age group was 18-30 yrs (58.7%). 
 
 In this study many cases were reported in September and October 
which is the rainy and pre monsoon period. This is similar to studies done 
by Jhansi Charles et al (2015) and Priyadarshini Shanmugam et al. (2016) 
which showed had peak incidence of cases during rainy and pre monsoon 
seasons. Since large number of cases occur during rainy and monsoon 
period, preventive measures have to initiated promptly like control of 
mosquitoes and rodents. The general public have to be educated and 
awareness should be created on good hygienic practices, vector control 
measures and protective measures. 
 
 In this study among 150 patients, the duration of fever range was 5-10 
days in 94% followed by 11-14 days in 6%. This was similar to study done 
by Das et al 2015, in which mean duration of fever was 5-7 days (92%). 
 
 In this study majority of the cases 126(84%) presented with fever 
with rigor & chills followed by nausea & vomiting 80 (53%), Headache 43 
(29%), abdominal pain (43%).  This was in contrast to study Das et al 2015 
in which myalgia 113(86%) were more common followed by headache 
84(68%). 
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 In this study blood samples from150 patients were subjected to blood 
culture/serological tested according to the duration of  fever. 5(3%) positive 
for enteric fever by blood culture, 9(6%) positive by widal test for enteric 
fever. 40(26.6%) were positive for Dengue, 31(21%) were positive for 
leptospirosis, 9(6%) were positive for malaria 9(6%) were positive for 
Enteric fever, 8(5%) were positive for scrub typhus, 6(4%) were positive for 
chikungunya. 31(21%) were unclassified because the etiology was not 
diagnosed based on these serological tests. 
 
 In this study Dengue infections among AUFI, patients were detected 
by NSI antigen in 17(11.3%) and IgM ELISA in 23(15%) and both were 
positive in 10 cases (6.6%). This was similar to study done by Vidhyarani 
2016, were more marked in Dengue cases with 40 cases of 
thrombocytopenia and 34 cases of leucopenia. In this study, 40(26.6%) were 
positive for Dengue. Fever was the commonest symptom for dengue in this 
study fever followed by headache (42). In this study thrombocytopenia 
32(21.3%) and leucopenia 25(16%). This was similar to the study conducted 
by Vidhyarani et al 2016, and by Yogesha et al 2014. 
 
 In this study detection of leptospirosis by MSAT among 150 patients 
was 31 (21%). Most common presentation of leptospirosis was fever 
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29(19%) followed by jaundice 27(18%). This was similar to study done by 
Neelu sree p. et. al 2015 where the detection rate of  leptospirosis was 22%. 
 
 In this study detection of malaria among 150 patients were 9(6%). By 
using peripheral blood smear the detection rate was 100% when compared 
to one step malaria Antigen rapid test which was 66%. The most common 
presentation of malaria was anaemia (9) followed by thrombocytopenia (3). 
This was similar to study done by Kashinkunti et al 2013 were detection rate 
was 100% in peripheral blood smear compared to rapid test (80%). 
 
 In this study scrub typhus and chikungunya were detected in 8(5%) 
and 6(4%) cases respectively. It was low when compared to the study by 
Kumar. V. et. al. 2014 and Dipmala Das et al 2015 were the prevalence was 
33%. This is due to geographical distribution of the causative agent. 
 
 Blood culture was positive in 5 cases for Salmonella typhi infection.  
and Widal test for salmonella Typhi positive (9) in this study. The similar 
study was done by Bhan mk, Bahl R, Bhatnagar, Lancet. 2005:366 
(9487):749-62. 
  
Summary 
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SUMMARY 
 The present study includes 150 patients admitted with Acute 
undifferentiated febrile illness 
 Among 150 patients 85(57%) were male and 65(43%) were females. 
 Most commonly affected age group were 18-30yrs (54.7%) followed 
by 31-40 yrs (22%). 
 Majority of cases were reported in September and October(68) 
followed by November and December (33). 
  Maximum duration of fever were 5-10 days (94%) followed by 11-14 
days (6%). 
 Majority of them presented with fever with rigor & chills 126(84%) 
followed by nausea and vomiting 80(53%). 
 Majority of them were positive for Dengue 40(26.6%) followed by 
leptospirosis 31(21%), malaria were positive in 9(6%), Enteric fever 
were positive in 9(6%) by widal test & one step RDT  positive 8(5%) 
for scrub typhus, 6(4%) were positive for chikungunya, 42(28%) of 
them were unclassified. 
 Among 50 patients positive for dengue 17 patients were detected by 
NSI antigen 33 by Dengue IgM ELISA . Majority of dengue patients 
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presented with fever (50) followed by headache (42), and showed 
thrombocytopenia (32) and leucopenia (18). 
 Among 150 patients 31(21%) were positive for leptospirosis detected 
by microscopic standard agglutination test (100%). 
 Among 150 patients, 9(6%) were positive for malaria and it was 
detected by peripheral smear (100%) 
 8(5%) and 6(4%) were positive for scrub typhus and chikungunya 
which was detected by Rapid card test and IgM ELISA kit 
respectively. 
  
Conclusion 
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CONCLUSION 
 
 In this study, 150 patients admitted with signs and symptoms of acute 
undifferentiated febrile illness patients were tested by blood culture and for 
various  serological tests according to the duration of fever. 40(26.6%) were 
positive for Dengue, 31(21%) were positive for leptospirosis, 9(6%) were 
positive for malaria, 9(6%) were positive for enteric fever by widal,  
8(5%) were positive for scrub typhus, 6(4%) were positive for chikungunya, 
and 42(28%) were negative for all these tests hence the etiology was not 
known. 
 
 Majority of them showed peak seasonal incidence of cases during 
rainy and post monsoon seasons, preventive measures have to initiated like 
control of mosquitoes, rodents and the general public have to be educate and 
awareness should be created on good hygienic practices, vector control 
measures and protective measures. 
 
 Although Dengue being the commonest cause of acute febrile illness, 
other different causes prevailing in tropical countries should be suspected 
and correct diagnosis is crucial to prevent the delay in starting appropriate 
therapy. 
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 Confirmatory diagnostic tests with good correlation of clinical 
findings, relevant laboratory parameters and epidemiology of disease is 
essential to prevent complications and to reduce morbidity and mortality in 
patients with acute febrile illness. 
 
 Antimicrobial susceptibility pattern wass in s.Typhi with re-
reemergence of susceptibility of ampicillin chloramphenical, and 
cotrimoxarole. S.Typhi was high resistance to Nalidixic  acid and 
pefloxacin. The use of pefloxacin as a surrogative marker for fluoroquinole 
susceptibility is promising, since it detects all the mechanisms for 
fluoroquinolone resistance in this study, and clearly separates peflax 
susceptibility and resistant strain. 
 
 In this study, unclassified 42 cases (28%) in which causes may be due 
to Influenza, Hepatitis B, Infective endocarditis, UTI and LRI. 
COLOUR PLATES 
 
 
 
Image 1 : Salmonella Typhi (Red Colour colonies with black center) 
 
 
 
 
 
Image 2 : Mac Conkey Agar Plate LF & NLF 
 
  
  
 
Image 3 : Life cycle of Malaria Parasite 
  
 
 
Image 4 : Stages of Plasmodium species 
  
  
 
Image 5 : Peripheral Smear for Malaria 
 
 
 
 
  
 
Image 6 : Positive and Negative NSI – Antigen   
  
 
Image 7 : Serum samples taken for Dengue early capture  
ELISA & ICT Card Test 
 
 
 
 
 
Image 8 : Serum samples taken for Dengue early capture 
ELISA & ICT Card Test 
  
  
 
Image 9 : Dengue NS1-Ag. Early capture ELISA microtiter plate  
shows positive & negative results 
 
 
 
 
 
 
Image 10 : Spectrophotometer (ELISA Reader) with Microtiter plate 
 
 
 
  
 
Image 11 : Dengue NSI Antigen Positive Strip 
 
 
 
 
 
Image 12 : Dengue NS – I Ag. Early Capture ELISA Test Kit  
(PANBIO) 
 
  
 
 
Image 13 : Blood culture bottles A. Monophasic medium (BHI broth) 
B. Biphasic medium (Castaneda’s), containing BHI broth and BHI agar 
 
 
 
 
 
Image 14 : Colourless colonies in Mac Conkey agar (NLF) 
  
 
 
 
 
Image 15 : ELISA Multiscan system 
 
 
  
 
 Image 16 : One Step Malaria Antigen Rapid Test 
 
 
 
 
 
Image 17 : One Step Scrub Typhus antibody test 
 
 
 
 
 
Image 18 : Triple Sugar Iron (TSI) Agar Test 
 
 
 
 
 
 
Image 19 : Leptospirosis (MSAT) 
 
 
 
 
 
 
 
Image 20 : Antibiotic Sensitivity pattern 
(Disc Diffusion Method) 
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 ANNEXURE-I 
 
ABBREVATIONS 
 
AUF  - Acute undifferentiated Fever 
AFI  - Acute Febrile Illness 
UUF  - Unclassified Undifferentiated Fever  
AUFI  - Acute Undifferentiated Febrile Illness 
MAC  - Mac Conkey Agar Plate 
BAP  - Blood Agar Plate 
NA  - Nutrient Agar Plate 
BHI  - Brain heart Infusion 
MH  - Mueller Hinton Agar Plate 
ELISA - Enzyme Linked Immuno Absorbant Assay 
DV  - Dengue Virus  
DF  - Dengue Fever 
DHF  - Dengue Haemorrhagic Fever 
DSS  - Dengue shock Syndrome 
MSAT - Microscope Slide Agglutination Test 
NS1  - Non Structural Protein 
OD  - Optical Density 
PH  - Meassure of acidity/basicity of a solution 
WHO  - World Health Organisation 
IgG  - Immunoglobulin G 
IgM  - Immunoglobulin M 
PGE  - Prostaglandin 
ULV  - Ultra Low Volume 
ICUT test - Indole, citrate, urease, Triple sugar iron test. 
H2S  - hydrogen sulfide 
 
Antibiotics 
Amp  - Ampicillin 
Cotri  - cotrimoxazole 
Nal  - Nalidixic acid 
Ck  - Chloramphenical 
Cef  - cefriaxone 
Pef  - pefloxacin 
  
APPENDIX – II 
 
A. Dengue NS1 Antigen 
 
Principle of the test 
 This is a solid phase enzyme linked immunosorbent assay (ELISA) based on the 
“Direct Sandwich” principle. The microwells are coated with Anti-dengue NS1 
antibodies with high reactivity for Dengue NS Ag. The samples are added in the wells 
followed by addition of enzyme conjugate (monoclonal anti-dengue NS1 antibodies 
linked to Horseradish Peroxidase (HRPO)). A sandwich complex is formed in the well 
wherein dengue NS1 (from serum sample) is “trapped” or “sandwiched” between the 
antibody and antibody HRPO conjugate. Unbound conjugate is then washed off with 
wash buffer. The amount of bound Peroxidase is proportional to the concentration 
dengue NS1 antigen present in the sample. Upon addition of the substrate buffer and 
chromogen, a blue colour develops. The intensity of developed blue colour is 
proportional to the concentration of dengue NS1 antigen is sample. To limit the enzyme-
substrate reaction, stop solution is added and a yellow colour develops which is finally 
read at 450nm spectrophotometrically. 
 
Kit & Its components 
Microwells  Microwells coated with anti-Dengue NS1         
                                   antibodies packed in a sealed pouch with desiccant 
 
Diluent  Buffer containing protein stabilizers & antimicrobial agents as  
   preservative and to be used for Sample & Conjugate dilution. 
  
Enzyme Conjugate    
Concentrate (50X)    Containing Monoclonal Anti-Dengue NS1 linked to horseradish  
   Peroxidase with protein stabilizers.                                                     
 
Wash Buffer 
Concentrate (25X) Concentrated phosphate buffer with surfactant. 
 
TMB Substrate TMB, to be diluted with TMB Diluent before use. 
 
TMB Diluent  Buffer solution containing H2O2 
 
Control(-)  Normal human serum negative for Dengue                     
       NS1 antigen with preservative. 
 
Control(+)  Recombinant Dengue NS1 antigen with Preservative 
 
Calibrator  Recombinant Dengue NS1 antigen with Preservative 
 
Stop solution  Ready to use, 1N H2SO4 
  
Plate sealers  Adhesive sheets to cover the microwells during  
    incubation. 
 
B. Dengue IgM Capture ELISA 
 
Principle of the test 
 
 Serum antibodies of the IgM class, when present, combine with anti-human IgM 
antibodies attached to the polystyrene surface of the microwell test strips. A concentrated 
pool of Dengue 1-4 Antigens is diluted to the correct working volume with Antigen 
Diluent. The antigens are produced using an insect cell expression system and 
immunopurified utilizing a specific monoclonal antibody. An equal volume of the HRP 
conjugated Monoclonal Antibody (MAb) is added to the diluted antigen, which allows 
the formation of antigen-MAb complexes. Residual serum is removed from the assay 
plate by washing, and complexed antigen-MAb is added to the assay plate. After 
incubation, the microwells are washed and a colourless substrate system, 
tetramethylbenzidine/hydrogen peroxide (TMB chromogen) is added. The substrate is 
hydrolysed by the enzyme and the chromogen changes to a blue colour. After stopping 
the reaction with acid, the T<B becomes yellow. Colour development is indicative of the 
presence of anti-dengue IgM antibodies in the test sample. 
 
Components 
Wash Buffer 20X Concentrate 
TMB Chromogen 
Stop solution 
Sample Diluent 
Antigen Diluent 
Dengue 1-4 Antigen 
Dengue IgM Capture MAb Tracer HRP 
Anti-Human IgM Antibody coated Microwells 
Dengue IgM capture positive control 
Dengue IgM capture calibrator 
Dengue IgM capture Negative control 
 
C. CHIKUNGUNYA IgM CAPTURE ELISA KIT 
Principle 
 IgM antibodies in the patient’s serum are captured by anti-human IgM (µ chain 
specific) coated on to the solid surface (wells). In the next step, CHIK antigen is added 
which binds to captured human IgM in the sample. Unbound antigen is removed during 
the washing step. In the subsequent step biotinylated anti CHIK monoclonal antibodies 
are added followed by Avidin-HRP. Subsequently, chromogenic substrate (TMB/H2O2) 
is added, the reaction stopped by 1N H2SO4. The intensity of color/optical density is 
measured at 450nm. 
 
COMPONENTS 
a) Anti Human IgM coated wells(96) Ready to use 
(Twelve strips with eight wells each) 
Ninety six polystyrene wells are coated with polyclonal rabit anti Human IgM and post 
coated to block non-specific binding of any protein; and also to stabilize the coated 
antibody. Stable at 2-8°c if protected from 
  
 
b) Sample Diluent for Chik IgM Ready to use 
One bottle (60ml)/kit. 
Phosphate Buffered Saline with additives to be used for dilution of test samples (serum). 
 
c) Wash Buffer Concentrate (20X) 
One bottle (60ml)/kit. 
Phosphate buffered saline with surfactant and antibioticsw. If the Wash Buffer 
Concentrate shows crystallization, warm the bottle at 37°c until crystallization 
disappears. Before use, dilute wash buffer concentrate 1:19 (1 part of buffer concentrate 
+ 19 parts of high grade distilled water). For essay of eight samples (six clinical samples 
and two controls), 100ml of diluted wash buffer is sufficient. 
 
d) Chikungunya Antigen Ready to use 
One vial (6ml)/kit 
CHIK antigen in stabilizer with additives. The antigen may show pink/yellowish color 
due to the phenol red indicator. Unused antigen must be decontaminated before it is 
discarded. 
 
e) Anti CHIK monoclonal antibody (Biotin labeled) Ready to use 
One vial (6ml)/kit. 
Anti CHIK Monoclonal Antibody-Biotin labeled diluted in stabilizer with additives and 
antibiotics. 
 
f) Avidin-HRP-Ready to use 
One vial (6ml)/kit. 
Avidin-HRP diluted in stabilizer with additives and antibiotics. Protect the solution from 
direct exposure to light. 
 
g) Liquid TMB substrate-Ready to use 
One vial (12ml)/kit. 
Tetramethylbenzidine Dihydrochloride. It is light sensitive. Protect from    light. 
 
h) Stop solution Ready to use 
One vial (12ml)/kit 
1 N H2SO4 wear protective gloves mask and eye glasses while handling stop solution. 
 
i) CHIK IgM Positive control Ready to use 
One vial (0.8ml)/kit 
Human serum positive for CHIK IgM antibodies diluted in stabili8zer with Additives. 
This is ready to use reagent. Do not dilute. 
 
j) CHIK IgM Negative Control Ready to use 
One vial (0.8ml)/kit 
Human serum Negative for CHIK IgM antibodies diluted in stabili8zer with Additives. 
This is ready to use reagent. Do not dilute. 
 
  
APPENDIX – III 
Preparations: 
     A.  Mac Conkey Agar 
     Uses: Cultivation and differentiation of Entro bacteria. 
 
Ingredients: 
Peptone   - 20gm/lit 
Lactose   - 10gm 
Neutral red   - 0.04  
Water     - 1 lit 
Sodium Taurochlotate   - 5gm 
Agar    - 5.0gm 
PH    - 7.4 ± 0.2 
Orange red, clear to slightly opalescent gel. 
 
Directions: 
     1. suspend 55.08ms of the powder in 1000ml of distilled water. 
     2. Mix thoroughly 
     3. Boil with frequent agitation to dissolve the powder completely. U.  
     4. Sterilize by autoclaving at 121°c (15 1bs pressure) for 15 minutes.  
         Quality control – E.coli (positive)  Shigalla flexneri.(Negative) 
 
B. Blood Agar 
It is enriched medium and indicator medium showing the haemolytic properties of 
bacteria. 
The medium is prepared by adding sterile blood to sterile nutrient agar that has been 
melted and cooled to 50°c. 
It consist of 10% sheep blood agar, double layered, and translucent. 
A thin layer of melted nutrient agar about 7ml for a 90cm petri dish, is poured and 
allowed to set. Then a similar thin layer of 10% sheep blood agar is poured on top of the 
first layer. 
 
C. Nutrient Agar 
Uses: For cultivation of less fastidious microorganisms can be enriched with blood and 
other body fluids. 
 
Ingredients: 
Peptone   - 5gms/lit 
Nacl    - 5gms/lit 
Meat extract (Beaf)  - 1.50gms/lit 
Yeast Extract   - 1.50gms/lit 
Agar    - 15gms/lit 
Water    - 1 lit 
 
  
Directions: 
Suspend 28.0gms in 1000mlof distilled water, Heat to boiling to dissolve the medium 
completely. 
Sterlize by autoclaving at 15Ibs pressure 121°c for 15 minutes. Cool to 45-50°c. Mix 
well and pour into the petri dish. 
 
D. Muller Hinton Agar 
Uses: For determination of susceptibility of micro organisms to Antibacterial agents. 
 
Ingredients: 
Meet infusion from  - 300.00 gms/lit 
Casein acid hydrolysate - 17.50 gms/lit 
Starch    - 1.50 gms/lit 
Agar    - 17.00 gms/lit 
Water    - 1 lit 
PH    - 7.3 ± 0.1 
 
Directions: 
Suspend 38.0 gms in 1000ml of distilled water. Heat boiling to dissolve the medium 
completely. Sterilize by Autoclaving at 15 Ibs pressure, 121°c for 15 minutes and cool to 
45-50°c mix well. 
 
E. Preparation of Leishman’s Stain: 
The stain is available in the form of powder or tablet. The strength of the solution used 
for staining is 0.15 per cent of the stain in methyl alcohol (0.15 gram of the stain is 
dissolved in 100 ml of acetone-free pure methyl alcohol). The materials required for 
preparation are a ground-glass stoppered bottle of 150ml capacity, a 100 ml graduated 
glass cylinder and a glass pestle and mortar. All the articles are thoroughly cleaned and 
before use, are rinsed with methyl alcohol. The amount of methyl alcohol (100 ml) is 
first measured in the graduated cylinder. The weighed amount of Leishman’s powder 
(0.15 g) or the requisite number of tablets (each tablet contains 0.15 g of the stain) is 
placed in the glass mortal and is ground into a paste by adding methyl alcohol in small 
quantities ( about 2 ml each time). The dissolved stain is carefully decanted off, from 
time to time, into the glass-stoppered bottle. The undissolved stain is ground again with 
methyl alcohol till no residue is left and the whole methyl alcohol has been used up. The 
stoppered glass-bottle with the stain is kept in an incubator at 37°c for 24 hours after 
which it is ready for use. 
  
 
 
  
 
 
  
S.No
Age 
(Years)
Sex
Duration of Fever 
(Days)
Rigger & 
Chills
Headache
Nausea & 
Vomiting
Joint Pain
Cough 
Dyspnea
Diarrhea 
& Loose 
Stools
Oliguria
Calf Muscles 
tenderness
Eschar
1 40 M 12  -   - - - - -
2 30 M 10 
3 26 M 5   
4 26 M 7    
5 35 M 6   
6 42 M 5   
7 35 F 6 
8 60 M 7  
9 35 M 6  
10 63 F 6 
11 40 F 10  
12 33 M 10  
13 42 M 10   
14 25 M 7 
15 19 F 5 
16 70 M 7 
17 21 F 5  
18 19 M 6   
19 18 M 6   
20 41 M 10  
21 23 M 8
22 22 M 7 
23 30 F 7  
24 18 M 9  
25 18 M 7   
26 18 F 8 
27 19 F 9 
28 23 M 7 
29 20 M 7 
30 18 F 7 
31 35 F 7    
32 28 M 7   
33 30 M 7  
MASTER CHART
S.No
Age 
(Years)
Sex
Duration of Fever 
(Days)
Rigger & 
Chills
Headache
Nausea & 
Vomiting
Joint Pain
Cough 
Dyspnea
Diarrhea 
& Loose 
Stools
Oliguria
Calf Muscles 
tenderness
Eschar
34 18 M 7  
35 25 M 5 
36 32 F 7  
37 19 F 10  
38 54 M 8   
39 45 F 7 
40 22 M 5 
41 30 M 6  
42 23 M 6  
43 34 F 6  
44 23 M 7  
45 35 M 8   
46 19 F 6  
47 65 M 7   
48 23 F 10   
49 21 M 7  
50 15 F 14  
51 45 M 12    
52 69 M 10   
53 49 F 8   
54 18 M 6 
55 48 F 8  
56 34 M 7  
57 80 F 12  
58 19 M 10   
59 45 F 10   
60 25 M 9   
61 21 M 8  
62 37 M 7  
63 32 M 7   
64 19 F 6  
65 20 F 8  
66 18 M 7   
67 19 M 6   
68 22 F 8 
S.No
Age 
(Years)
Sex
Duration of Fever 
(Days)
Rigger & 
Chills
Headache
Nausea & 
Vomiting
Joint Pain
Cough 
Dyspnea
Diarrhea 
& Loose 
Stools
Oliguria
Calf Muscles 
tenderness
Eschar
69 29 F 9  
70 38 F 7  
71 45 M 7   
72 30 F 8  
73 19 F 7   
74 35 M 9  
75 53 M 10  
76 18 M 8  
77 25 M 9   
78 36 M 7  
79 65 F 7  
80 40 F 5 
81 56 F 12
82 19 F 10 
83 45 F 8  
84 34 F 6   
85 46 F 10  
86 25 M 7   
87 50 F 5   
88 65 M 14   
89 19 F 7 
90 39 M 6 
91 18 F 7  
92 19 F 7 
93 25 F 10   
94 19 M 5   
95 39 F 4    
96 37 F 5  
97 45 F 14   
98 19 M 5 
99 34 M 5   
100 58 F 7  
101 23 F 7  
102 58 M 7    
103 34 M 7  
S.No
Age 
(Years)
Sex
Duration of Fever 
(Days)
Rigger & 
Chills
Headache
Nausea & 
Vomiting
Joint Pain
Cough 
Dyspnea
Diarrhea 
& Loose 
Stools
Oliguria
Calf Muscles 
tenderness
Eschar
104 33 M 14  
105 36 F 5  
106 22 M 5  
107 36 F 5   
108 29 M 6  
109 57 M 7  
110 25 M 5   
111 42 F 7  
112 35 F 10    
113 50 F 7
114 33 F 4
115 20 F 4  
116 19 F 5   
117 18 M 8   
118 24 M 7  
119 33 M 4 
120 40 F 10  
121 26 M 7 
122 25 F 7   
123 65 M 7  
124 19 M 7   
125 28 F 7   
126 18 M 8   
127 33 F 14    
128 45 F 7  
129 23 F 7  
130 65 M 7   
131 57 M 6  
132 28 M 10   
133 30 M 7
134 21 F 7   
135 18 M 5  
136 24 M 7
137 29 M 9
138 35 F 10
S.No Rash Jaundice Arthralgia
Altered 
Sensorium
Abd. Pain
Bleeding 
Manifes.
Retroarbital Pain
Haemata
mesis
WBC 
Count
Platelet 
count
S. Bilirubin SGOT IU/L SGPT IU/L
1 25000 188 129
2 30000 212 130
3 
4  4x10 3ul
5  4000 2 156 128
6  4x10 3ul
7  4x10 3ul 3000 2.4 144 112
8   2.6
9 4500
10 4000
11   26000
12 
13  3x10 3ul
14 3500
15   
16  4000
17 3500
18   4500
19 4000
20
21 30000 3.2
22 Anemia 3
23 
24   2.4
25   2.6
26   3.7x10 2.8
27  2.6
28  2.4
29  2
30  1.4
31 2.8 176 124
32 Anemia
33   1.8
34    2.6 12 14
35
36   4.18x10
37 20000
38 19000
39
40   2000 86 72
S.No Rash Jaundice Arthralgia
Altered 
Sensorium
Abd. Pain
Bleeding 
Manifes.
Retroarbital Pain
Haemata
mesis
WBC 
Count
Platelet 
count
S. Bilirubin SGOT IU/L SGPT IU/L
41
42   3.5x10
43 4000
44  2000
45  3000
46 3.5x10
47 2500
48 Anemia
49 4000
50 Anemia
51  3000 142 126
52 
53  19000
54  30000
55 4000
56 
57 2000 1.8
58   3.5x10 1.9 16 12
59 
60 5.5x10
61  20000 24 14
62   30000 38 16
63  47 14
64  
65 128 119
66  Anemia
67  114 105
68  19000 88 76
69   
70 9478
71   26000
72  30000
73  84 76
74    
75 
76   20000 104 94
77    4.5x10
78   39000 124 112
79
80  4.3x10 1.9
S.No Rash Jaundice Arthralgia
Altered 
Sensorium
Abd. Pain
Bleeding 
Manifes.
Retroarbital Pain
Haemata
mesis
WBC 
Count
Platelet 
count
S. Bilirubin SGOT IU/L SGPT IU/L
81  3.5 2.4
82  4.5 2.2 143 109
83 anemia
84 40000
85  2.2
86 18000 153 114
87
88   4x10
89   1.9
90
91  20000 2.4
92   2.6
93  1.2 109 98
94  1.8
95  2.4
96  Anemia
97   18000 146 112
98   19000
99 
100    30000
101 
102 45000
103  
104   164 148
105   2.5
106 
107   20000
108  22000
109   25000
110 20000
111
112   2.6
113   2.4
114   2.9
115  3.6
116  2.8
117   1.9
118  2.4
119  3.2
120
S.No Rash Jaundice Arthralgia
Altered 
Sensorium
Abd. Pain
Bleeding 
Manifes.
Retroarbital Pain
Haemata
mesis
WBC 
Count
Platelet 
count
S. Bilirubin SGOT IU/L SGPT IU/L
121  1.9
122 2.9
123    20000
124  
125 20000
126  4.2
127  
128  4.3 1.9
129    4
130  3.7
131  
132    19000
133    20000
134  20000
135 Anemia
136   18000
137
138
139
140    14.3x10
141
142  4.5x10
143 
144  
145
146
147
148   3.5x10
149
150
S.No
Age 
(Years)
Sex
Duration of Fever 
(Days)
Rigger & 
Chills
Headache
Nausea & 
Vomiting
Joint Pain
Cough 
Dyspnea
Diarrhea 
& Loose 
Stools
Oliguria
Calf Muscles 
tenderness
Eschar
139 24 M 7
140 43 F 5   
141 19 M 5    
142 21 M 5   
143 18 M 7   
144 19 M 8  
145 19 F 5   
146 25 M 5   
147 28 F 6   
148 23 M 7     
149 33 M 7  
150 42 F 7  
S.No Urine Albumin Blood Culture
Peripheral Smear 
(MP)
Malarial Ag
Dengue Ns1 
Ag
Dengue IgM 
ELISA
Chickungunya 
IgM ELISA
MSAT Widal
Scrub 
TyPhus
Un 
classified
1 - - - - Positive Positive - - - - -
2 - - - - Positive Positive - - - - -
3 - - - - Positive - - - - -
4 - - - - - - - - Positive - -
5 - - - - - - - Positive2+ - -
6 - - - - - - - Positive - -
7 - - - - - - - Positive2+ - - -
8 - - - - - - - Positive2+ - - -
9 - - - - Positive - - - - -
10 - - - - Positive - - - - -
11 - - - - Positive - - - - -
12 - - - - - - - Positive2+ - - -
13 - - Positive - - - - - - - -
14 - - - - Positive - - - - -
15 - - - - - Positive - - - -
16 - - Positive - - - - - - - -
17 - Positive - - - - - - - - -
18 - - - - - - - - - Positive
19 - - - - - - Positive - -
20 - - - - - - - - -
21 - - - - - Positive - - -
22 - - Positive Positive - - - 
23 - - - - - - - Positive2+ - - -
24 - - - - - - Positive - - -
25 - - - - - - - - - -
S.No Urine Albumin Blood Culture
Peripheral Smear 
(MP)
Malarial Ag
Dengue Ns1 
Ag
Dengue IgM 
ELISA
Chickungunya 
IgM ELISA
MSAT Widal
Scrub 
TyPhus
Un 
classified
26 - - - - - - - Positive2+ - - -
27 - - - - - - - - - Positive -
28 - - - - - - - - - Positive -
29 - - - - - - - - - Positive -
30 - - - - - - - - - Positive -
31 - - - - - - - - - - -
32 - - Positive Positive - - - - -
33 - - - - - Positive - - - - -
34 - Positive - - - - - - - -
35 - - - - Positive Positive - - - - -
36 - - - - - - - - - - 
37 - - - - - - Positive - - -
38 - - - - - - - - - - 
39 - - - - Positive - - - - - -
40 - - - - Positive Positive - - - - -
41 - - - - - - Positive - - - -
42 - - - - - - - - Positive - -
43 - - - - - Positive - - - -
44 - - - - - Positive - - - -
45 - - - - - - - Positive - -
46 - - - - - - - Positive - -
47 - - - - - Positive - - - - -
48 - - Positive Positive - - - - - - -
49 - - - - - - - Positive2+ - - -
50 - - Positive - - - - - -
51 - - - Positive - - - - - -
52 Positive - - - - - - - -
53 - - - - Positive - - - - - -
54 - - - - Positive
S.No Urine Albumin Blood Culture
Peripheral Smear 
(MP)
Malarial Ag
Dengue Ns1 
Ag
Dengue IgM 
ELISA
Chickungunya 
IgM ELISA
MSAT Widal
Scrub 
TyPhus
Un 
classified
55 - - - - Positive
56 - - - - Positive2+
57 - - - - 
58 - - - - Positive2+ Positive
59 - - - - 
60 - - - - 
61 - - Positive Positive
62 - - Positive
63 
64 
65 
66
67
68 Positive
69 
70 
71 Positive
72 Positive Positive
73 
74 
75 
76 Positive
77 Positive Positive
78 Positive
79 
80 Positive2+
81 Positive Positive2+
S.No Urine Albumin Blood Culture
Peripheral Smear 
(MP)
Malarial Ag
Dengue Ns1 
Ag
Dengue IgM 
ELISA
Chickungunya 
IgM ELISA
MSAT Widal
Scrub 
TyPhus
Un 
classified
82 Positive Positive2+
83 Positive Positive
84 Positive
85 Positive2+
86 Positive Positive
87 
88 Positive
89 Positive Positive2+
90 Positive 
91 Positive
92 Positive Positive2+
93 
94 Positive2+
95 Positive2+
96 Positive Positive
97 Positive
98 Positive Positive
99 
100 Positive
101 
102 Positive
103 
104 
105 Positive2+
S.No Urine Albumin Blood Culture
Peripheral Smear 
(MP)
Malarial Ag
Dengue Ns1 
Ag
Dengue IgM 
ELISA
Chickungunya 
IgM ELISA
MSAT Widal
Scrub 
TyPhus
Un 
classified
106 
107 Positive
108 Positive
109 Positive2+
110 Positive
111 
112 Positive2+
113 Positive2+
114 Positive3+
115
116 Positive2+
117 Positive2+
118 Positive2+
119 Positive2+
120 Positive
121 Positive2+
122 Positive2+
123 Positive Positive
124 
125 Positive Positive
126
S.No Urine Albumin Blood Culture
Peripheral Smear 
(MP)
Malarial Ag
Dengue Ns1 
Ag
Dengue IgM 
ELISA
Chickungunya 
IgM ELISA
MSAT Widal
Scrub 
TyPhus
Un 
classified
127 Positive2+
128 Positive
129 Positive2+
130 Positive2+
131 
132 Positive
133 Positive
134 Positive
135 Positive
136 Positive
137 
138 
139 
140 
141 
142 Positive
143 Positive
144 
145 Positive
146 
147 
148 
149 
150 
